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Finasteride is in present a relatively frequent prescribed drug for male androgenic alopecia. The 
adverse effects reported by some patients seem to be notable, consisting of various (physical, mental/ 
neurological, sexual, etc.) manifestations which are encountered both during Finasteride administration 
and after treatment cessation (in the form of `post-Finasteride syndrome`).  
The pharmacological action and the corresponding adverse effects related to Finasteride 
administration were investigated and published in literature through several and successive studies. In 
respect to psychiatric disorders, the most notable concern is related to depressive symptoms and suicidal 
thoughts among former users of finasteride with persistent adverse effects. Regarding genito-urinary 
symptoms, these are usually represented by gynecomastia, decreased interest in sexual intercourse/ low 
level of sexual desire and erectile dysfunction.  
Finally, we viewed Finasteride side effects and post-Finasteride syndrome as distinct physio-
pathologic entities, thus requiring possible distinct therapeutic approaches. Additional studies will be 
necessary, in order to further investigate the cerebral neuromodulation of the two relational (cognitive 
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and sexual) functions, both of which may be interfered by administration of hormones or by the 
corresponding compounds such as Finasteride.   
 
Introduction 
Male androgenic alopecia (known also as male androgenetic alopecia, male-pattern hair loss, or 
male pattern baldness) is the most frequent cause of hair loss, affecting up to 50% of men and 40% of 
women by the age of 50 (1). Usually, women lose hair in diffuse patterns over the top of the scalp, while 
men present a hairline/ balding delineation at the temples and vertex. Even so, multiple and relatively 
common (genetic, environmental, etc.) factors are involved, in both men and women (2). The most 
common treatment methods are represented by finasteride and minoxidil administration, with some 
studies also suggesting tretinoin, ketoconazole and spironolactone (3, 4).   
Finasteride is a competitive inhibitor for 5 alpha-reductase enzyme, being currently used as a 
pharmacological therapeutic approach of male androgenic alopecia and benign prostatic hyperplasia. 
Administration of Finasteride is able to induce behavioral changes to animals, while in humans 
depressive symptoms were relatively frequently reported. For this reason, it was recommended for 
Finasteride to be carefully administered to patients presenting a history or a high risk to developing 
depression (5).      
With respect to antiandrogenic treatment, in previously published studies it was investigated the 
sexual side effects of Finasteride and Tamoxifen, specifically as related to handedness of the participants 
(6, 7). The results showed that sexual hormones could exert a cerebral neuromodulation of the dorsal/ 
thalamic route, which is according to lateralization process of the brain (8). Moreover, these results and 
other partial published data delineated within the brain the ventral/ hypothalamic input (afferent) route, 
as a common neural network underlying both abstract cognition and sexuality (perhaps under 
pheromonal modulation) (9). It is in part a continuation of a previous published paper, which argues for 
somatic peripheral afferents that serve processes underlying cognition and sexual response (10). 
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A new study regarding Finasteride side effects and post-Finasteride syndrome in a sample of 
men with male androgenic alopecia was currently performed (8, 11). Taking advantage of data already 
published through a series of separate investigations, the intent of this paper is to consolidate these 
findings into a unitary perspective for understanding Finasteride action and the distribution of 
psychiatric and sexual side effects within the sample of men with androgenic alopecia. This perspective 
includes attention to both neuroendocrinological and neuropsychological systems that impinge upon 
both cognitive and sexual processing of information. Further empirical studies will be necessary to 
clarify the proposed perspective regarding cerebral neuromodulation of sexual function via hormones 
and pheromones, as a possible premise for understanding the existing cerebral interferences between 
cognition and sexuality.   
 
Discussion 
Finasteride is a competitive 5 alpha-reductase inhibitor for type II and III isoenzymes, preventing 
thus conversion of testosterone to dihydrotestosterone. As a consequence, the serum level of 
dihydrotestosterone decreases after Finasteride administration with about 65–70%. The partial inhibition 
of dihydrotestosterone synthesis is due to the fact that Finasteride doesn’t inhibit the type I of 5 alpha-
reductase isoenzyme (1, 2).  
  Decreasing the level of dihydrotestosterone, Finasteride contributes to reduction of GABAA 
activity (dihydrotestosterone helps activation of GABAA receptors), which has been involved in 
depression, anxiety and sexual dysfunctions. Yet, Finasteride decreases androgen activity in the scalp 
and prostate (8, 11). 
1. Finasteride side effects  
In a preliminary study regarding Finasteride side effects, the right-handed men reported on the 
most IIEF subscales either no effect or lower sexual functioning, while the left-handed men presented 
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either no effect or improved sexual function. These results differed substantially from previously 
published studies examining finasteride sexual side effects, a result that may have been due to the more 
precise way in which it was defined the “relevant sexual activity.” Thus, the patients were alerted to the 
possibility of either positive or negative sexual effects, assessing separately the effects in right-handed 
vs left-handed patients. Handedness, as a possible proxy for cognitive style and lateralization process of 
the brain, appears to be a fairly reliable predictor when considering the sexual side effects of specific 
antiandrogenic compounds (6).  
In that study, it was taken into account only the subject’s hand preference, which is strongly 
related to anatomical dichotomy/ lateralization process of the brain. For this reason the samples were 
grouped based on right and left handedness, and the results interpreted accordingly—as mentioned 
above, right-handed men presented either no effect or lower sexual function while left-handed men 
reported either no effect or improved sexual function. However, the informational dichotomy related to 
hypothalamic route was not incorporated into this interpretation, because the potential role for this factor 
was unclear/ unknown to us at that time (6).   
Subsequent investigations were then designed to investigate not only the anatomical but also the 
informational/ hypothalamic dichotomy of sexuality (examining relationships among sexual hormones, 
pheromones, cognitive and sexual laterality of information processing). This study was undertaken in 
part to identify factors that might be responsible for men showing no effect vs those showing either 
enhanced or diminished sexual function. Accordingly, it was found that the right-handed men 
demonstrated either no effect (group B, sensitive to female pheromones) or lower sexual function (group 
C, sensitive to androgens/ antiandrogens such as Finasteride), while the left-handed men noted either no 
effect (group A, sensitive to male pheromones) or improved sexual function (group D, which would be 
sensitive to estrogens/ antiestrogens such as Tamoxifen) (7, 8, 11). From this study, it was concluded 
that there is also an informational/ hypothalamic dichotomy that affects sexual response (in addition to 
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anatomical dichotomy), presumably with sexual pheromones acting on the hypothalamic input route but 
sexual hormones acting on the thalamic input route (7, 8).  
 
2. Post-Finasteride syndrome 
Multiple clinical studies show that Finasteride administration induces in some patients various 
(physical, mental/ neurological, sexual, etc.) adverse effects, which may be either reversible or persistent 
after treatment cessation. When persistent (even at three months after medication cessation), the 
respective side effects are named `post-Finasteride syndrome` (12). We consider that the `post-
Finasteride syndrome` should be differentiated from side effects occurring to Finasteride (during the 
drug administration), even if symptoms are relatively similar and successive during treatment vs 
posttreatment. On one hand, patients treated for male pattern hair loss with finasteride show, after 
discontinuation of the drug, a persistent altered level of some neuroactive steroids in cerebrospinal fluid 
and plasma (13). On the other hand, in preliminary studies Finasteride side effects (occurring during 
Finasteride administration) occurred especially to right handed men, while the post-Finasteride 
syndrome (occurring after Finasteride administration) were encountered not only in androgenic-sensitive 
(right handed) men but also in estrogenic-sensitive (left handed) men (11). 
In order to understand this new approach, we can resort to a suggestive example. Thus, selective 
serotonin reuptake inhibitors (SSRIs) increase serotonin available at serotonergic synapses. In contrast, 
tianeptine is a drug that decreases serotonin at serotonergic synapses. Yet although the pharmacologic 
actions of the two drugs are opposite, both drugs have the capacity to decrease clinically depressive 
symptoms (14). Along similar lines, finasteride side effects (occurring during finasteride administration) 
and post-finasteride syndrome (occurring after finasteride administration) may share common clinical 
manifestations, yet this does not require that these two conditions act similarly with respect to 
pharmacologic/ physio-pathologic mechanisms.   
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Finally, it was found that the post-finasteride symptoms were relatively similar after various 
doses, administered for two distinct medical conditions (male pattern hair loss and benign prostatic 
hyperplasia) (15). In subjects with benign prostatic hyperplasia, the post-finasteride syndrome seems to 
lesser in magnitude, due perhaps to the fact that such patients have greater tolerance to treatment (a 
better adaptation/  a disease with a greater impact on the health), or due to an increased mean age (with 
possible implications on lifestyle). Such factors could be assessed and controlled in future studies. 
 
Conclusions 
Male androgenic alopecia is a moderately stressful condition for which patients often resort to a 
medical assistance, due to the fact that it seriously diminishes body image satisfaction. Early stages of 
the hair loss can be slowed or reversed through medication; finasteride being one of the drugs that are 
used for this condition, with a proved efficacy.  
Even if at first glance it might seem that the finasteride use is pretty safe, in fact it is not so. 
Recent studies show the fact that androgenic alopecia may actually underlie to depressive symptoms and 
suicidal thoughts among former users of finasteride with persistent sexual side effects (16). These side 
effects of finasteride are still under evaluation, a relatively difficult process due to the fact that 
physiologies of mental and sexual functions (often affected by finasteride) are only now being clarified. 
On the other hand the post-finasteride syndrome is only a recently recognized entity, which needs to be 
further studied with respect to symptomatology and therapeutic approach.  
The current paper, we believe, offers a better understanding of Finasteride action as well as 
prediction of sexual side effects; furthermore, our current line of investigation aimed at specifying 
factors related to the distribution of sexual side-effects related to Finasteride administration could help 
develop models regarding the neural processing of sexual information as well as the representation of 
sexual information in the mind that ties to both sexual desire and arousal. Such ideas remain under 
exploration.     
 Finasteride side effects in androgenic alopecia 
148 
 
Acknowledgments: This work was supported by a grant of the Ministry of National Education, CNCS-
UEFISCDI, project number: PN-II-ID-PCE- 2012-4-0409 
 
Disclosure 
No authors involved in the production of this article have any commercial associations that might 
pose or create a conflict of interest with information presented herein. 
 
References 
1. Tosti A, Camacho-Martinez F, Dawber R. Management of androgenetic alopecia.  J Eur Acad 
Dermatol Venereol. 1999; 12(3): 205-14. 
2. Nyholt DR, Gillespie NA, Heath AC, Martin NG. Genetic basis of male pattern baldness. J Invest 
Dermatol. 2003; 121(6): 1561-4.  
3. Mirmirani P, Consolo M, Oyetakin-White P, Baron E, Leahy P, Karnik P. Similar response patterns 
to topical minoxidil foam 5% in frontal and vertex scalp of men with androgenetic alopecia: a 
microarray analysis. Br J Dermatol. 2015; 172(6): 1555-61. 
4. Levy LL, Emer JJ. Female pattern alopecia: current perspectives.  Int J Womens Health 2013; 5: 
541-56. 
5. Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a 
prospective study. BMC Clin Pharmacol. 2006; 6: 7. 
6. Motofei IG, Rowland DL, Georgescu SR et al. A pilot study on the sexual side effects of finasteride 
as related to hand preference for men undergoing treatment of male pattern baldness. BJU Int. 2013; 
111(4): E221-6.  
7. Motofei IG, Rowland DL, Popa F et al. A Pilot Study on Tamoxifen Sexual Side Effects and Hand 
Preference in Male Breast Cancer. Arch Sex Behav. 2015; 44(6): 1589- 94. 
8. Motofei IG, Rowland DL, Paunica S, Tampa M, Georgescu SR. Lateralized sexual side effects of 
Finasteride in subjects with androgenic alopecia. J Invest Dermatol. 2014; 134: S69.  
 Finasteride side effects in androgenic alopecia 
149 
 
9. Motofei IG, Rowland DL. The ventral-hypothalamic input route: a common neural network for 
abstract cognition and sexuality.  BJU Int. 2014; 113(2): 296-303. 
10. Motofei IG. A dual physiological character for cerebral mechanisms of sexuality and cognition: 
common somatic peripheral afferents.  BJU Int. 2011. 108(10): 1634-9. 
11. Gerogescu SR, Tampa M, Paunica S et al. Distribution of post-finasteride syndrome in men with 
androgenic alopecia. J Invest Dermatol. 2015; 135: S40. 
12. Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-
finasteride: a survey of men reporting symptoms.  Am J Mens Health. 2015; 9(3): 222-8.  
13. Caruso D, Abbiati F, Giatti S et al. Patients treated for male pattern hair with finasteride show, after 
discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. 
J Steroid Biochem Mol Biol. 2015; 146: 74-9.  
14. Seidel S, Dal-Bianco P, Pablik E et al. Depressive Symptoms are the Main Predictor for Subjective 
Sleep Quality in Patients with Mild Cognitive Impairment-A Controlled Study. PLoS One. 2015; 
10(6): e0128139.  
15. Motofei IG, Rowland DL, Georgescu SR et al. The post-finasteride syndrome after distinct doses/ 
affections. J Invest Dermatol. 2015; 135: S40. 
16. Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with 
persistent sexual side effects. J Clin Psychiatry. 2012; 73(9): 1220-3.  
